A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-577

To Learn More Call
201-510-0910